Good Vs. Right Money: Choosing Optimal Financing Avenues For Biotech

Access to capital is often a great limiter for biotechs. When money does become available, it’s nearly impossible to pass it up. But especially in current times with capital being relatively more accessible, companies must proceed cautiously when considering what potential investors and other capital sources bring to the table. In times of crisis, having the right money invested in a company can make all the difference for continuing survival and return to growth.

A panel session at the Therapeutic Area Partnerships Meeting in Boston late last year considered the issues that face biotech executives and investors in selecting among various ways of financing...